Cue Biopharma Inc’s recent filing unveils that its Director Sarraf Pasha acquired Company’s shares for reported $99747.0 on Dec 30 ’25. In the deal valued at $0.31 per share,323,857 shares were bought. As a result of this transaction, Sarraf Pasha now holds 323,857 shares worth roughly $0.11 million.
Then, MATTEO GIACOMO LEVISETTI bought 7,230 shares, generating $1,907 in total proceeds.
Jefferies initiated its Cue Biopharma Inc [CUE] rating to a Buy in a research note published on March 13, 2024; the price target was $6. Piper Sandler began covering CUE with “an Overweight” recommendation on November 21, 2022. H.C. Wainwright started covering the stock on January 13, 2022. It rated CUE as “a Buy”.
Price Performance Review of CUE
On Friday, Cue Biopharma Inc [NASDAQ:CUE] saw its stock jump 10.48% to $0.34. Over the last five days, the stock has gained 40.00%. Cue Biopharma Inc shares have fallen nearly -66.92% since the year began. Nevertheless, the stocks have risen 10.48% over the past one year. While a 52-week high of $1.75 was reached on 01/02/26, a 52-week low of $0.23 was recorded on 01/02/26.
Levels Of Support And Resistance For CUE Stock
The 24-hour chart illustrates a support level at 0.3079, which if violated will result in even more drops to 0.2784. On the upside, there is a resistance level at 0.3559. A further resistance level may holdings at 0.3744.
How much short interest is there in Cue Biopharma Inc?
A steep rise in short interest was recorded in Cue Biopharma Inc stocks on 2025-12-15, dropping by -0.14 million shares to a total of 0.37 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 0.51 million shares. There was a decline of -38.2%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 03, 2022 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
